BACKGROUND AND OBJECTIVE: Although biphenotypic leukemia is now a defined entity, outcome of this rare form of acute leukemia has not been well documented. We present the first comprehensive study analyzing induction and consolidation therapy of biphenotypic leukemia and correlate outcome to prognostic factors. DESIGN AND METHODS: In this retrospective study, the incidence of biphenotypic leukemia was found to be 3.6% from 693 adult and pediatric acute leukemias referred to our center for treatment over the last 8 years. Of these, 15 were B-lymphoid/myeloid, 8 were T-lymphoid/myeloid, one was T/B lymphoid and one had trilineage differentiation. RESULTS: Induction of remission in de novo cases was achieved in 70% of patients and relapse of disease occurred in 15%. The use of combined lymphoid and myeloid drugs for induction resulted in a high incidence of early deaths (25%). The overall probability of survival at 2 years was 39.4%. Patients with secondary disease had a uniformly poor outcome with low remission rates and high relapse rates. INTERPRETATION AND CONCLUSIONS: Prognosis was most strongly related to the presence of the Philadelphia chromosome (p=0.03) and age under 15 years (p=0.01). We conclude that patients with biphenotypic leukemia should have risk stratification with treatment tailored to their prognostic factors.
BACKGROUND AND OBJECTIVE: Although biphenotypic leukemia is now a defined entity, outcome of this rare form of acute leukemia has not been well documented. We present the first comprehensive study analyzing induction and consolidation therapy of biphenotypic leukemia and correlate outcome to prognostic factors. DESIGN AND METHODS: In this retrospective study, the incidence of biphenotypic leukemia was found to be 3.6% from 693 adult and pediatric acute leukemias referred to our center for treatment over the last 8 years. Of these, 15 were B-lymphoid/myeloid, 8 were T-lymphoid/myeloid, one was T/B lymphoid and one had trilineage differentiation. RESULTS: Induction of remission in de novo cases was achieved in 70% of patients and relapse of disease occurred in 15%. The use of combined lymphoid and myeloid drugs for induction resulted in a high incidence of early deaths (25%). The overall probability of survival at 2 years was 39.4%. Patients with secondary disease had a uniformly poor outcome with low remission rates and high relapse rates. INTERPRETATION AND CONCLUSIONS: Prognosis was most strongly related to the presence of the Philadelphia chromosome (p=0.03) and age under 15 years (p=0.01). We conclude that patients with biphenotypic leukemia should have risk stratification with treatment tailored to their prognostic factors.
Authors: Bas J Wouters; Meritxell Alberich Jordà; Karen Keeshan; Irene Louwers; Claudia A J Erpelinck-Verschueren; Dennis Tielemans; Anton W Langerak; Yiping He; Yumi Yashiro-Ohtani; Pu Zhang; Christopher J Hetherington; Roel G W Verhaak; Peter J M Valk; Bob Löwenberg; Daniel G Tenen; Warren S Pear; Ruud Delwel Journal: Blood Date: 2007-08-01 Impact factor: 22.113
Authors: Bartlomiej M Getta; Mikhail Roshal; Junting Zheng; Jae H Park; Eytan M Stein; Ross Levine; Esperanza B Papadopoulos; Ann A Jakubowski; Nancy A Kernan; Peter Steinherz; Richard J O'Reilly; Miguel-Angel Perales; Sergio A Giralt; Martin S Tallman; Brian C Shaffer Journal: Biol Blood Marrow Transplant Date: 2017-07-08 Impact factor: 5.742
Authors: Ester Mejstrikova; Jana Volejnikova; Eva Fronkova; Katerina Zdrahalova; Tomas Kalina; Jaroslav Sterba; Yahia Jabali; Vladimir Mihal; Bohumir Blazek; Zdena Cerna; Daniela Prochazkova; Jiri Hak; Zuzana Zemanova; Marie Jarosova; Alexandra Oltova; Petr Sedlacek; Jiri Schwarz; Jan Zuna; Jan Trka; Jan Stary; Ondrej Hrusak Journal: Haematologica Date: 2010-02-09 Impact factor: 9.941
Authors: Pia Riemke; Melinda Czeh; Josephine Fischer; Carolin Walter; Saeed Ghani; Matthias Zepper; Konstantin Agelopoulos; Stephanie Lettermann; Marie L Gebhardt; Nancy Mah; Andre Weilemann; Michael Grau; Verena Gröning; Torsten Haferlach; Dido Lenze; Ruud Delwel; Marco Prinz; Miguel A Andrade-Navarro; Georg Lenz; Martin Dugas; Carsten Müller-Tidow; Frank Rosenbauer Journal: EMBO J Date: 2016-08-29 Impact factor: 11.598
Authors: Amal S Al-Seraihy; Tarek M Owaidah; Mouhab Ayas; Hassan El-Solh; Mohammed Al-Mahr; Ali Al-Ahmari; Asim F Belgaumi Journal: Haematologica Date: 2009-08-27 Impact factor: 9.941